Free public records show Nanjing IASO Biotechnology Co., Ltd. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Nanjing IASO Biotechnology Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
10 active studies led by Nanjing IASO Biotechnology Co., Ltd., of 12 in all
Source: ClinicalTrials.gov, Studies with Nanjing IASO Biotechnology Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Nanjing IASO Biotechnology Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Nanjing IASO Biotechnology Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Nanjing IASO Biotechnology Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Nanjing IASO Biotechnology Co., Ltd. is in.
Stories on the topics Nanjing IASO Biotechnology Co., Ltd. works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
Sequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics…
Read
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
ReadSearch all reports for Nanjing IASO Biotechnology Co., Ltd. All companies